<DOC>
	<DOCNO>NCT01636648</DOCNO>
	<brief_summary>This prospective , non-randomized , multi-center , non-interventional post-market study . The study post-market long-term follow-up study base cohort patient ( 148 patient ) enrol previous investigational study March 2007 December 2009 ( ATS 3f Enable™ Aortic Bioprosthesis Model 6000 , number S2005 ) involve 10 European site . Patient follow-up take place yearly basis 10 year implant/enrollment . Medtronic ATS Inc. retain right terminate study time 5 year followup . The primary objective study evaluate safety effectiveness Medtronic ATS Enable Aortic Bioprosthesis long-term follow-up . As observational study , safety efficacy data summarize described . There statistically power study hypothesis .</brief_summary>
	<brief_title>Enable I Long-term Follow-up Study</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Aortic Valve Insufficiency</mesh_term>
	<criteria>Patients enrol implanted ATS 3f Enable™ Aortic Bioprosthesis Model 6000 , number S2005 Patient willing sign new Data Release form ( DRF ) Patient Informed Consent ( PIC ) postmarket study ( applicable study due local requirement regulation ) ATS 3f Enable™ Aortic Bioprosthesis Model 6000 explanted Patient die Patient lose followup Patient withdrew</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Aortic Valve Replacement</keyword>
	<keyword>Aortic Valve Bioprosthesis</keyword>
</DOC>